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Abstract
Objective—We examine remission rate probabilities, recovery rates, and residual symptoms across
36 weeks in the Treatment for Adolescents with Depression Study (TADS).
Method—TADS, a multisite clinical trial, randomized 439 adolescents with major depressive
disorder (MDD) to 12 weeks of treatment to fluoxetine (FLX), cognitive behavioral therapy (CBT),
their combination (COMB), or pill placebo (PBO). The PBO group, treated openly after week 12,
was not included in the subsequent analyses. Treatment differences in remission rates and
probabilities of remission over time are compared. Recovery rates in remitters at week 12 (acute
phase remitters) and week 18 (continuation phase remitters) are summarized. We also examined
whether residual symptoms at the end of 12 weeks of acute treatment predicted later remission.
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Results—At Week 36, the estimated remission rates for intention-to-treat cases were: COMB: 60%,
FLX: 55%; CBT: 64%; overall: 60%. Paired comparisons reveal that at week 24 all active treatments
converge on remission outcomes. The recovery rate at Week 36 was 65% for acute phase remitters
and 71% for continuation phase remitters, with no significant between-treatment differences in
recovery rates. Residual symptoms at the end of acute treatment predicted failure to achieve remission
at weeks 18 and 36.
Conclusions—The majority of depressed adolescents in all three treatment modalities achieved
remission at the end of nine months of treatment.
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Introduction
In recent years, our understanding of acute treatment outcomes in pediatric depression has
increased; however, much less is known about the long-term outcomes following acute
treatment. Guidelines on continuation and maintenance phase treatments in youth have been
proposed, but few studies have specifically investigated the effectiveness of interventions in
these phases of treatment, particularly with respect to remission and recovery.1–2 Most of the
reports on later outcomes in treatment in this age group are from naturalistic follow-up studies.
The Treatment for Adolescents with Depression Study (TADS) included an acute phase of
treatment (Stage I, 0 í12 weeks) followed by a continuation phase (Stage II, 12 to 18 weeks)
and a maintenance phase component (Stage III, weeks 18 to 36). In this paper we evaluate the
remission and recovery rates through week 36 in the TADS sample.
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Few reports of remission rates after acute treatment in pediatric depression are available. The
most common efficacy outcome in clinical trials is response, typically defined as a clinician
rating of improvement. Remission, a more stringent outcome, is defined as a return to a
symptom free or near symptom free status. Brent and colleagues reported a remission rate of
64.7% (defined as absence of MDD on the K-SADS-P/E and 3 consecutive weekly scores on
the Beck Depression Inventory, BDI, of < 9).3 Birmaher and colleagues, in a 12- to 16- week
psychotherapy trial, reported a remission rate of 64% at the end of acute treatment.4 Remission
rates in antidepressant trials in youth range from 23% to 63%.5–6 Recently the TADS reported
on remission rates, defined as the attainment of a Childhood Depression Rating Scale-Revised
(CDRS-R)7 score of  28 at the end of acute treatment.6 The remission rate across treatment
groups was only 23% after twelve weeks of acute treatment. Although the rate of remission
for the combination treatment of fluoxetine and cognitive behavioral therapy (CBT) was the
highest of the four treatment arms, at 37%, it is clearly a less than optimal rate given that this
represents the most intensive and effective treatment available to date for adolescent
depression.8
Reports of remission outcomes during the continuation phase of treatment in children with
depression are rare. Birmaher and colleagues report a cumulative remission rate of 83.7% over
a 2-year period.4 In adult studies of continuation treatment for depression, rates of remission
in continuation treatment (“late remitters”) range from 30–53%.9–11
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Relatively little is known about sustained remission or recovery in continuation care. A recent
ACNP task force recommended that recovery be defined as the achievement of remission which
is sustained by a well period of at least four months.12 Much of the adult literature to date uses
terms of sustained remission, or maintained remission. The rates of maintenance of remission
in adults effectively treated for depression range from 67 to 86%.9–11 Combination treatment
appears to have higher rates of remission maintenance compared to those who received either
monotherapy.11
There have been more investigations of longer-term outcomes in recovery. Clarke and
colleagues examined continuation phase recovery rates in adolescents after acute phase group
CBT with or without parent group.13 Continuation phase recovery rates at one year were: 100%
(5/5) for booster sessions and 50% (6/12) in the two assessment conditions (p < .05). While
booster sessions were associated with better continuation phase outcomes, the study was
limited by its small sample size. In addition, Birmaher and colleagues found an 80% recovery
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rate at the 2-year follow-up of an acute psychotherapy trial.4 Finally, naturalistic follow-up
studies of pediatric depression have found that the average rates of recovery from first-episode
MDD range from nine to twelve months.14–15
In adult depressed patients, reaching remission in acute care resulted in better follow-up
outcomes than merely achieving responder status.12 Regardless of response status, the presence
of residual symptoms after acute treatment for major depressive disorder (MDD) has been
found to increase the risk of relapse in adults.16–18 Similarly, partial remission was related to
poor outcomes in both medication and CBT trials.17,19–23 In the TADS trial, among patients
having an adequate treatment response (defined as very much improved or much improved on
the Clinical Global Impressions-Improvement scale, CGI-I),24 50% had one or more residual
symptoms at the end of acute treatment.6 While few studies have investigated whether the
presence of residual symptoms in youth is associated with poorer outcomes, a recent report
suggests that, similar to adults, youth with residual symptoms at the end of acute treatment are
at a high risk for relapse.25 In addition, having subsyndromal depressive symptoms in
adolescence places youth at risk for slower recovery, subsequent major depression, and other
negative outcomes such as substance abuse.26–28
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TADS was a controlled clinical trial of pharmacotherapy with fluoxetine (FLX), CBT, their
combination (COMB), or clinical management with pill placebo (PBO) in adolescents with
MDD. The rationale, design, and methods for the study are presented in previous reports.29–
30 In addition, the primary outcome results from the acute treatment phase and the long-term
outcomes of the study have been reported.31–32 The initial report of 36 week outcomes
demonstrates that all three active treatments converged with respect to clinical response, with
over 80% showing response in each group. In this report, we present the continuation and
maintenance phase outcomes on remission and recovery, which typically are considered to be
more stringent outcomes than response or sustained improvement.

Method
Study Participants
The methods for the TADS have been described in prior publications.29,31,33 The original
TADS sample was comprised of 439 adolescents who met DSM-IV criteria for MDD and had
a CDRS-R score of 45 or greater at study entry. The demographic and clinical characteristics
of the TADS sample are presented in a prior report.33 Study participants were randomized to
one of the four treatment conditions: COMB (n=107), FLX (n=109), CBT (n=111), and PBO
(n=112).
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All 439 teenagers randomized to treatment were encouraged to continue assessments
throughout the 36-week period regardless of treatment compliance, termination of randomized
treatment, or use of concomitant treatments. The two blinded conditions (PBO and FLX) were
unveiled and the PBO arm was discontinued at the end of the 12-week acute treatment phase
(Stage I), regardless of treatment response. PBO-treated patients who were partial or non
responders at the end of Stage I were followed in open treatment by TADS clinicians. PBO
responders were offered phone follow-up and their choice of the three active TADS treatments
upon relapse. Only those youth randomized to active treatment (COMB, FLX, and CBT) who
were a full responder or partial responder at the end of Stage I continued in their randomized
treatment arm during the subsequent six-week consolidation phase (Stage II) which was
followed an 18 week maintenance phase (Stage III). Full response was defined by the clinician
as CGI-I score of 1 (very much improved) or 2 (much improved) at the end of Stage I, while
partial response was indicated by a CGI-I score of 3 (minimally improved).

J Am Acad Child Adolesc Psychiatry. Author manuscript; available in PMC 2010 March 22.
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During Stage I, participants in a medication arm (i.e., FLX, COMB, and PBO) received an
initial 60-minute visit, followed by 20- to 30-minute visits with the study psychiatrist over the
12 weeks of treatment. The initial visit included an education component, and all visits
consisted of assessment of patient status and side effects monitoring. Both PBO and FLX began
with one week of 10 mg/day, followed by an increase to 20 mg/day. From week 4 through the
remainder of acute treatment, dose increases (10 mg/day increments) were based on response
and tolerability to a maximum of 40 mg/day. Beginning with the week 12 visit, the dose could
be increased up to a maximum of 60 mg/day in partial responders and the dose for the fullresponders was continued for those adolescents in the COMB and FLX arms. In Stage II, full
responders had two office visits and partial responders had four office visits. In Stage III, the
medication dose remained constant unless adverse events required a dose reduction and patients
were followed at 6-week intervals.
TADS CBT in Stage I consisted of 15 60-minute sessions. COMB and CBT participants
determined by the clinician to be partial responders at week 12 received six additional weekly
sessions in Stage II. Stage I full responders received biweekly CBT session in stage II. In the
18-week Stage III maintenance phase participants had three “booster” sessions, each 6 weeks
apart. COMB participants received all the components of medication management and CBT.
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Measures
Participants were assessed by a blinded Independent Evaluator (IE) at baseline, as well as weeks
6, 12 (end of Stage I acute treatment), 18 (end of Stage II), 24, 30, and 36 (end of Stage III).
The IE provided the ratings for the measures described below.
The CDRS-R,7 a 17-item clinician-rated measure of depression severity with each item rated
on a scale of 1 to 5 or 1 to 7, was completed at each IE assessment. The total score was based
on the synthesis of information from interviews with the adolescent and the parent. Interrater
reliability on the CDRS-R at baseline (intraclass correlation coefficient of .95) and week 12
(intraclass correlation coefficient of .98) was high.33
The CGI-I measures the clinician’s impression of improvement rated relative to baseline
severity.24 This seven–point Likert scale was completed by the IE. Responder status was
defined by an end of acute treatment score of “very much improved” or “much improved” (i.e.,
1 or 2 respectively) and partial response was defined as a CGI-I of 3. Treatment dosing and
continuation, however, was determined by the treating clinician’s CGI-I ratings.

NIH-PA Author Manuscript

The Schedule for Affective Disorders and Schizophrenia for School-Age Children--Present
and Lifetime version (K-SADS-PL)34 was completed at baseline and then repeated at week 12
(end of acute treatment) to determine the presence of residual symptoms. A depressive
symptom was rated as present or not present, with the threshold for presence being defined as
a score of at least 3.
Concomitant treatment and medication logs, as well as a modified version of the Child and
Adolescent Services Assessment (CASA)35 documented mental health treatment received
outside of TADS. The CASA assesses mental health service utilization (defined as inpatient
or outpatient services for emotional, behavioral or substance problems).
Definition of Remission, Recovery, and Residual symptoms
Remission for the analyses in this manuscript is defined as CDRS-R  28. This definition is
consistent with previous definitions of remission in the child and adolescent psychiatry
literature.6,36–38 Recovery was determined using two subsamples: 1) remitters at week 12
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(acute phase remitters) and 2) remitters at week 18 (continuation phase remitters, i.e. those not
remitted at week 12). In acute phase remitters, participants were defined as recovered if they
retained remission status at weeks 18, 24, 30, and 36. For the continuation phase remitters,
recovery was defined as retaining remission at weeks 24, 30, and 36. A residual symptom was
defined as the presence of a score of at least one affective symptom on the K-SADS-PL at
week 12.

Data Analysis
The primary analyses of remission rates, recovery rates, and impact of residual symptoms were
conducted using an “intention-to-treat” (ITT) approach in which the analysis included all
participants randomized to treatment regardless of protocol adherence and/or treatment
completion. Analyses were conducted to examine remission rates (a) during the 12-week acute
treatment phase in the four treatment conditions (Stage I) and (b) across the 36-week treatment
period in those youth randomized to one of the three active treatment arms (Stages I–III).
Because the PBO condition was discontinued at the end of Stage I, this arm was excluded from
the Stage I–III analyses.
For Stage I, the ITT analysis (N=439) included the data from all participants randomized to
treatment For Stages I–III, the ITT analysis focused on the youths randomized to COMB, FLX,
and CBT arms at the beginning of Stage I (N=327).
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A longitudinal data analysis approach was employed and were designed to examine remission
rates in the treatment arms during the post-randomization period. Generalized linear mixed
models (GLMM) for binary outcomes applying a Generalized Estimating Equations (GEE)
method with a logit link function for a binomial distribution were used to compare treatment
differences in remission rates across time and estimate the probabilities of remission over time
for the treatment arms. These hierarchical mixed model tested for fixed effects of site,
treatment, time, and the treatment-by-time interactions and the random effects of patient and
patient-by-time. The initial models included site and its two-and three-way interactions.
Because the site interactions were not statistically significant (p > .05), these interactions were
omitted from the final analytic models while retaining the main effect of site since treatments
were nested within clinical site. The original 13 clinical sites were collapsed into ten sites32–
33 so as to adjust for three low enrolling sites which were affecting the stability of the analytic
models. More specifically, each low enrolling site was combined with another site with similar
baseline demographics and treatment effects to form one site. For the 28 adolescents who
dropped out of the study before completing the first post-baseline assessment, their week 6
score was set to 0 (no remission) given that all patients met criteria for major depression and
a CDRS-R total of 45 or greater at baseline.
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Chi-square tests were used to determine whether residual symptoms at Week 12 are associated
remission at weeks 18 and 36. All analyses were conducted using SAS 8.2® and the level of
significance was set at 0.05 for each statistical test. A posteriori paired comparisons were
conducted only if the omnibus test was significant at the 0.05 level for treatment or treatmentby-time effects.

Results
Baseline Characteristics
Table 1 presents the baseline demographic and clinical characteristics for adolescents included
in the Stage (N=439) and Stages I–III (N=327) ITT analyses. There were no statistically
significant differences between treatment groups on any of the baseline measures for any of
the analysis samples.
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The remission rates, using predicted scores from the GEE method, for Stage I cases at the end
of acute treatment were: COMB: 39%; FLX: 24%; CBT: 19%, PBO: 19%. With the PBO arm
included, the overall rate was 26% for the ITT cases. Although the treatment-by-time
interaction was not significant (Ȥ2 = 7.54, df = 3, p < .06), the main effects for treatment (Ȥ2 =
24.26, df = 3, p < .0001) and time (Ȥ2 = 32.87, df = 1, p < .0001) were significant. Site was a
significant covariate (p = .0029). Because the main effect of treatment was statistically
significant, we conducted paired contrasts at week 12. COMB had a significantly higher
remission probability at week 12 compared to FLX (Ȥ2 = 4.64, df = 1, p = .0313), CBT (Ȥ2 =
8.52, df = 1, p = .0035), and PBO (Ȥ2 = 8.77, df = 1, p=.0031). These results are consistent
with the week 12 findings reported by Kennard et al (2006) using a logistic regression model
controlling for site and applying a last observation carried forward imputation method.
Stages I–III Remission Rates for the Three Active Treatment Conditions
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Figure 1 presents estimated remission rates based on the predicted probabilities of remission
derived from the GEE method for the three active treatment arms across assessments. The
overall estimated remission rate for the 327 cases in the three active treatment arms was 27%
at week 12, 40% at week 18, and 60% at week 36. The analysis indicated that the main effects
of treatment (Ȥ2 = 10.95, df = 2, p = .0042) and time (Ȥ2 = 127.43, df = 5, p < .0001) were
significant, as were the treatment-by-time interactions (Ȥ2 = 32.96, df = 10, p = .0003). Site
was also a significant predictor (p = .0022).
Paired comparisons revealed that at week 24 all active treatments converged on remission
outcomes (Table 2). COMB and FLX were superior to CBT at Week 6 (COMB vs CBT, p = .
0001; COMB vs FLX, p = .0068), while COMB was superior to both monotherapies at Weeks
12 (COMB vs CBT, p = .0033; COMB vs FLX, p = .0261) and 18 (COMB vs CBT, p = .0002;
COMB vs FLX, p = .0087). The estimated remission rates, Stage I – III, for the COMB, FLX
and CBT groups were 39%, 24% and 19%, respectively at week 12, while the estimated
remission rates at week 18 were 56%, 37%, and 27%, respectively. At week 36, the estimated
remission rates were: COMB: 60%, FLX: 55%; CBT: 64%; overall: 60%.
Recovery Rates in Acute and Continuation Phase Remitters
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Table 3 summarizes recovery rates, defined as maintaining remission once achieved, at
subsequent assessments for patients who were: (a) remitters at end of Week 12 (acute phase
remitters) and (b) remitters at the end of Week 18 (continuation phase remitters). The recovery
rate at Week 36 was 65% for the acute phase remitters and 71% for the continuation phase
remitters. Chi-square analyses indicated no significant between-treatment differences in
recovery rates at each subsequent assessment for the acute and continuation phase remitters.
Stage I Residual Symptoms and Remission
Residual symptoms were defined by the nine MDD items from the K-SADS-PL Week 12
assessments. For Stages I–III analyses that include youths randomized to one of the three active
treatment arms, the total number of residual symptoms at Week 12 in remitters was 0.28 ± 0.62
and in non-remitters was 3.24 ± 2.23. Total number of residual symptoms at week 12 was
significantly correlated with remission status at Weeks 18 (r = í0.52, p < .0001) and 36 (r =
í0.37; p < .0001), with a greater number of symptoms at week 12 associated with non-remission
status at both weeks 18 and 36.
Treatment within and outside of the TADS Study
Table 4 presents descriptive data on participants receiving treatment within and outside of
TADS for each treatment stage of the study. Overall these findings demonstrate that in Stages

J Am Acad Child Adolesc Psychiatry. Author manuscript; available in PMC 2010 March 22.

Kennard et al.

Page 7

NIH-PA Author Manuscript

I and II, most of the combination participants remained in their assigned treatment arm, while
many in monotherapy did not (between 34 to 46%). Furthermore, those initially assigned to
monotherapy, in Stages II and III frequently added the monotherapy that they were not already
receiving (FLX added psychosocial treatment, and CBT added an antidepressant medication).

Discussion
In this study, we report on later remission rates in pediatric depression. Earlier we reported on
acute remission outcomes for the TADS sample,6 with 23% of patients having achieved
remission. Although this rate was relatively low, the present report found that later remission
rates are considerably better. By week 36 the overall estimated remission rate is around 60%,
more than doubling the rate found at week 12. This remission rate is comparable to the overall
cumulative remission rate found in the STAR*D trial, which was 67%.39 These findings
highlight the importance of continuation and maintenance phase treatments, as the rates of
remission improve with time and continued treatment. While the outcome for the majority of
patients who continue in treatment is promising, it is important to recognize that a substantial
number of patients who undergo nine months of treatment fail to achieve remission.
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Combination treatment and fluoxetine monotherapy achieved significantly higher rates of
remission early in treatment (Week 6), compared to CBT (only 4%). The combination of
fluoxetine and CBT was superior to both monotherapies at weeks 12 and 18. By week 24 all
active treatment conditions converged on rates of remission. The superiority of combination
treatment over both monotherapies at week 18 is especially important to note, as all treatment
conditions were open label beginning at week 12. Thus, selecting a monotherapy treatment
could mean a delay of remission for a substantial number of depressed adolescent patients by
two to three months. These findings mirrored the longer-term outcomes recently reported on
response rates.32
Between 65 and 72% of adolescents who reached remission during acute treatment maintained
it through continuation and maintenance therapies. Thus, these adolescents had recovered from
their depression as defined by the ACNP definition of recovery, which is sustained remission
for four months.12 No differences were found on rates of recovery across treatment groups.
This recovery rate was similar to the rates of sustained remission as reported in the adult
literature (67 – 86%).9–11 While not statistically significant, it does appear that those remitters
who received CBT monotherapy had slightly higher rates of recovery (ranging from 77.8 to
87.5%), which is consistent with findings in the adult depression CBT outcome literature.40
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Conversely, one third of patients achieving remission did not maintain remission during
continuation and maintenance treatments. This finding has important clinical implications, as
it highlights the need to continue to monitor patients even after they have reached remission
status. Furthermore, the loss of remission status in one third of patients may have
methodological implications in future studies of remission. For example, a last observation
carried forward (LOCF) approach to this missing data in analyses of remission may be
misleading, as it may not capture variations in remission rates over time.
The presence of residual symptoms provided important prognostic information on later
remission achievement. Greater numbers of symptoms remaining at the end of 12 weeks of
treatment were predictive of later remission status. This was true at both 18 and 36 weeks.
Finally, participants assigned to combination treatment tended to stay in TADS COMB.
However, those assigned to a TADS monotherapy tended to augment with either medication
(in the case of CBT) and with psychosocial treatment (in the case of FLX) in later stages of
treatment. It is unclear if this was based on a clinician decision or a patient decision, but it
suggests that there is a belief that combination treatment is preferable.
J Am Acad Child Adolesc Psychiatry. Author manuscript; available in PMC 2010 March 22.
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These findings should be evaluated in light of the adopted definitions of remission and
recovery, possible influence of mere passage of time, and experimental sample size. An
accepted definition of remission, based on normative data (i.e., CDRS-R  28) was used for
these analyses; however a different definition might result in different findings. In addition,
we were restricted to measuring remission according to a set assessment schedule, and thus
were not able to capture or properly analyze timing of remission.
Although we found that remission rates improved over time and concluded that this was related
to continued treatment, it is possible that the mere passage of time contributed partially or fully
to higher remission rates. Studies of depressed youth which include long term follow-up
assessments frequently find that experimental groups and control groups converge on later
outcomes.41 Furthermore, Kovacs has reported that the length of an episode is typically 9
months with most youth having recovered by one year.14–15 It is possible, that at 36 weeks,
our patients were out of their episode as a result of time and not treatment. However, the mean
episode duration in the study was greater than one year and more than half the sample had
received prior treatment, yet these participants continued to meet criteria for depression (i.e.,
had not recovered).33 Thus, in our sample, spontaneous remission is unlikely, due to the illness
severity of these patients and past treatment of this sample.33
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Our study is also limited by the design in which all participants were in open treatment after
week 12. For ethical reasons, we could not create and follow an untreated group of depressed
adolescents for nine months. To truly evaluate the effects on continuation treatment, one would
need to conduct an RCT of continuation care versus a control condition, such that of Emslie
and colleagues.25 Finally, the smaller sample sizes at subsequent weeks due to attrition and
removal of the PBO arm may have limited our ability to adequately investigate questions of
treatment group differences and their impact on the achievement and maintenance of remission.
Despite the early low remission rates, the majority of depressed adolescents go on to achieve
remission after nine months of treatment. Methods of achieving higher or more rapid remission
rates are still needed. A better understanding of which remitted patients will fail to maintain
their recovery and how to better assist them is also necessary. Clinicians should be particularly
attentive to the presence of residual symptoms remaining after initial treatment response.
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Schoenholz; Johns Hopkins University: John Walkup, Golda Ginsburg, Elizabeth Kastelic, Hyung Koo; University
of Nebraska: Christopher Kratochvil, Diane May, Randy LaGrone, Brigette Vaughan; New York University: Anne
Marie Albano (now at Columbia), Glenn S. Hirsch, Elizabeth Podniesinki, Angela Chu; University of Chicago/
Northwestern University: Mark Reinecke, Bennett Leventhal, Gregory Rogers, Rachel Jacobs; Cincinnati Children's
Hospital Medical Center: Sanjeev Pathak, Jennifer Wells, Sarah Arszman, Arman Danielyan; University of Oregon:
Paul Rohde, Anne Simons, James Grimm, Stephenie Frank; University of Texas Southwestern: Graham Emslie, Beth
Kennard, Carroll Hughes, Taryn L. Mayes; Wayne State University: David Rosenberg, Nili Benazon, Michael Butkus,
Marla Bartoi; and Kelly Posner for the Columbia University Suicidality Classification Group. James Rochon (Duke
Clinical Research Institute) is statistical consultant. The opinions and assertions contained in this report are the private
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views of the authors and are not to be construed as official or as reflecting the views of the National Institute of Mental
Health, the National Institutes of Health, or the Department of Health and Human Services.
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Figure 1.

Estimated Remission Rates Across 36 Weeks for the Active Treatments Groups
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Clinical Global Impression – Severity (CGI-S): rated by blinded Independent Evaluator
Children’s Global Assessment Scale (CGAS): rated by blinded Independent valuator
COMB: combination of fluoxetine and cognitive behavior therapy
FLX: Fluoxetine therapy alone
Major Depressive Episode (MDE): K-SADS-PL diagnosis, rated by blinded Independent Evaluator
Number of current co-morbidities: Number of current DSM-IV comorbidities, including dysthymia
PBO: Placebo
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1
1
1
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1
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ITT = Cases in the Stages I-II Intent-to-treat analysis
CBT: Cognitive Behavioral Therapy alone
COMB: Combination of fluoxetine and cognitive behavior therapy
FLX: Fluoxetine therapy alone
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Week 30

Week 24

Week 18

Week 12

Week 6

Assessment

0.34

0.63

0.40

0.73

0.49

0.72

0.45
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0.67

0.75

1.24

1.82

0.67
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Remission Rates Paired Contrasts for the Three Active Treatment Arms

NIH-PA Author Manuscript

Table 2
Kennard et al.
Page 14

J Am Acad Child Adolesc Psychiatry. Author manuscript; available in PMC 2010 March 22.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Acute Phase Remitters

83

All

25
115

All

82 (71.3%)

20 (80.0%)

24 (66.7%)

36

FLX
CBT

54 (65.1%)

14 (77.8%)

15 (60.0%)

38 (70.4%)

70

Week 36
25 (62.5%)

54

COMB

18

16

20

25

FLX
CBT

Week 18
34

Week 12
40

COMB

Treatment

ITT = Cases in the Stages I–II Intent-to-treat. Recovery was determined using two subsamples: 1) remitters at week 12 (acute phase remitters) and 2) remitters at week 18 (continuation phase remitters). In
acute phase remitters, participants were determined to have recovered if they retained remission status at weeks 18, 24, 30, and 36. For the continuation phase remitters, recovery is defined as retaining remission
at weeks 24, 30, and 36. Percents are relative to number of youth in the remission on subgroup.
CBT: Cognitive Behavioral Therapy alone
COMB: Combination of fluoxetine and cognitive behavior therapy
FLX: Fluoxetine therapy alone

Continuation Phase Remitters

Remitter Subgroup

Analysis

Stage I–III ITT

Subsequent Recovery Rates by Treatment Arm in Remitters at the End of the Acute Treatment Phase (Week 12) and Continuation of Treatment Phase (Week
18)
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Table 4
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Treatment Interventions Received Within TADS
Randomized Treatment

N

Stage 1
Acute Treatment

Stage 2
Continuation Treatment

Stage 3
Maintenance Treatment

107 (100.0%)

78 (72.9%)

75 (70.1%)

FLX alone intervention

0 (0.0%)

2 (1.9%)

5 (4.7%)

CBT alone intervention

0 (0.0%)

7 (6.5%)

5 (4.7%)

0 (0.0%)

20 (18.7%)

22 (20.6%)

107

COMB
COMB intervention

No TADS intervention
109

FLX
COMB intervention
FLX alone intervention

0 (0.0%)

0 (0.0%)

0 (0.0%)

107 (98.2%)

75 (68.8%)

63 (57.8%)

CBT alone intervention

0 (0.0%)

0 (0.0%)

0 (0.0%)

No TADS intervention

2 (1.8%)

34 (31.2%)

46 (42.2%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

111

CBT
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COMB intervention
FLX alone intervention

0 (0.0%)

0 (0.0%)

0 (0.0%)

CBT alone intervention

110 (99.1%)

77 (69.4%)

65 (58.6%)

No TADS intervention

1 (0.9%)

34 (30.6%)

46 (41.4%)

Psychiatric Interventions Received Outside of TADS
Randomized Treatment

N

Stage 1
Acute Treatment

Stage 2
Continuation Treatment

Stage 3
Maintenance Treatment

4 (3.7%)

4 (3.7%)

5 (4.7%)

107

COMB
SSRI
Other anti-depressant

4 (3.7%)

4 (3.7%)

5 (4.7%)

Mood stabilizer

1 (0.9%)

0 (0.0%)

0 (0.0%)
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Anti-anxiety medication

0 (0.0%)

0 (0.0%)

0 (0.0%)

Psychostimulant

5 (4.7%)

6 (5.6%)

6 (5.6%)

CBT

0 (0.0%)

0 (0.0%)

2 (1.9%)

Other psychosocial therapy

1 (0.9%)

1 (0.9%)

8 (7.5%)

6 (5.5%)

7 (6.4%)

7 (6.4%)

109

FLX
SSRI
Other anti-depressant

7 (6.4%)

8 (7.3%)

7 (6.4%)

Mood stabilizer

0 (0.0%)

1 (0.9%)

3 (2.8%)

Anti-anxiety medication

0 (0.0%)

3 (2.8%)

2 (1.8%)

Psychostimulant

5 (4.6%)

4 (3.7%)

5 (4.6%)

CBT

2 (1.8%)

5 (4.6%)

6 (5.5%)

Other psychosocial therapy

9 (8.3%)

15 (13.8%)

18 (16.5%)

13 (11.7%)

16 (14.4%)

21 (18.9%)

CBT
SSRI

111
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Treatment Interventions Received Within TADS
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Randomized Treatment

Stage 1
Acute Treatment

Stage 2
Continuation Treatment

Stage 3
Maintenance Treatment

14 (12.6%)

17 (15.3%)

22 (19.8%)

Mood stabilizer

1 (0.9%)

0 (0.0%)

1 (0.9%)

Anti-anxiety medication

0 (0.0%)

1 (0.9%)

1 (0.9%)

Other anti-depressant

N

Psychostimulant

0 (0.0%)

1 (0.9%)

0 (0.0%)

CBT

1 (0.9%)

1 (0.9%)

4 (3.6%)

Other psychosocial therapy

4 (3.6%)

5 (4.5%)

10 (9.0%)

As per protocol, randomized treatment was continued at the end of acute treatment stage only if the youth was determined by the treating clinician to
be a full or partial treatment responder as defined by a CGI-I score of 1 (very much improved) or 2 (much improved) or 3 (minimally improved).
CBT: Cognitive Behavioral Therapy alone
COMB: Combination of fluoxetine and cognitive behavior therapy
FLX: Fluoxetine therapy alone
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